과제정보
연구 과제 주관 기관 : Korea Health Industry Development Institute (KHIDI)
참고문헌
- Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-2972. https://doi.org/10.1182/blood-2007-10-078022
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. https://doi.org/10.3322/caac.21254
- Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412-3420. https://doi.org/10.1200/JCO.2005.04.242
- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. https://doi.org/10.1016/S0140-6736(00)04046-0
- Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867. https://doi.org/10.1038/nature01322
- Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-1212. https://doi.org/10.1158/1055-9965.EPI-14-0146
- Zahorec R. Ratio of neutrophil to lymphocyte counts: rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14.
- McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534-540. https://doi.org/10.1016/j.ctrv.2012.08.003
- Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
- Keam B, Ha H, Kim TM, et al. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015;56:2032-2038. https://doi.org/10.3109/10428194.2014.982642
- Kelkitli E, Atay H, Cilingir F, et al. Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol 2014;93:841-846. https://doi.org/10.1007/s00277-013-1978-8
- Koh YW, Kang HJ, Park C, et al. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol 2012;138:846-854. https://doi.org/10.1309/AJCPO46GFKGNXCBR
- Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS One 2015;10:e0143080. https://doi.org/10.1371/journal.pone.0143080
- Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-737.
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863-2869. https://doi.org/10.1200/JCO.2015.61.2267
- Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269-277. https://doi.org/10.1038/leu.2013.247
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol 2011;90:423-428. https://doi.org/10.1007/s00277-010-1130-y
- Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-48490. https://doi.org/10.1074/jbc.R400025200
- Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009;32:471-482.
- Kim SJ, Kim K, Kim BS, et al. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. Acta Haematol 2009;122:200-210. https://doi.org/10.1159/000253027
- Jung SH, Kim JS, Lee WS, et al. Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. Ann Hematol 2016;95:55-61. https://doi.org/10.1007/s00277-015-2521-x
- Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 1999;66:981-988. https://doi.org/10.1002/jlb.66.6.981
- Sakamaki S, Hirayama Y, Matsunaga T, et al. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood 1999;94:1961-1970.
- Fritz E, Ludwig H, Scheithauer W, Sinzinger H. Shortened platelet half-life in multiple myeloma. Blood 1986;68:514-520.
피인용 문헌
- Prognostic role of neutrophil–lymphocyte ratio in multiple myeloma: a dose–response meta-analysis vol.11, pp.None, 2017, https://doi.org/10.2147/ott.s153146
- Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatmen vol.16, pp.5, 2017, https://doi.org/10.3892/ol.2018.9365
- Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience? vol.12, pp.7, 2020, https://doi.org/10.3390/cancers12071966
- Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis vol.11, pp.None, 2017, https://doi.org/10.3389/fonc.2021.766672
- Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transpl vol.193, pp.1, 2017, https://doi.org/10.1111/bjh.16806